Different conformational responses of the β2-adrenergic receptor-Gs complex upon binding of the partial agonist salbutamol or the full agonist isoprenaline

Fan Yang, Shenglong Ling, Yingxin Zhou, Yanan Zhang, Pei Lv, Sanling Liu, Wei Fang, Wenjing Sun, Liaoyuan A. Hu, Longhua Zhang, Pan Shi, Changlin TianNational 2020 · DOI

TL;DR

This study uses cryo-electron microscopy to reveal the distinct structural conformations of the β₂-adrenergic receptor (β₂AR)-Gs protein complex when bound to a partial agonist (salbutamol) versus a full agonist (isoprenaline). These structural differences explain why partial agonists lead to weaker signaling and desensitization, offering crucial insights into GPCR activation and drug development.

What Problem Does This Paper Address?

G protein-coupled receptors (GPCRs) are a vast family of cell surface receptors that mediate a wide range of physiological responses. They are activated by extracellular ligands, and the "efficacy" of these ligands—how strongly they activate the receptor—can vary significantly. While it's known that different efficacies lead to different receptor conformations and downstream signaling outcomes, the precise structural basis for these differences, particularly at the level of the GPCR-G protein complex, remains incompletely understood. This gap hinders our ability to design drugs with specific efficacy profiles and predict their therapeutic effects and side effects, such as receptor desensitization (a decrease in response upon prolonged stimulation). This paper aims to elucidate the structural mechanisms by which partial and full agonists differentially activate the β₂AR-Gs complex, providing a molecular explanation for their varying efficacies and desensitization properties.

Methods

The primary technique employed is single-particle cryo-electron microscopy (cryo-EM). This method allows researchers to determine the three-dimensional structure of macromolecular complexes at near-atomic resolution. The authors specifically used cryo-EM to visualize the β₂AR-Gs complex in two distinct states: one bound to the partial agonist salbutamol and the other to the full agonist isoprenaline. They achieved resolutions of 3.26 Å and 3.80 Å, respectively, which are sufficient to resolve key structural features and interactions.

In addition to cryo-EM, the study also references functional assays, specifically cAMP accumulation assays, to correlate structural findings with biological activity. Alanine mutagenesis was used to probe the role of specific residues in ligand binding and signaling.

Datasets

The study does not introduce new benchmark datasets. Instead, it relies on the structural data generated from their cryo-EM experiments of the β₂AR-Gs complex bound to salbutamol and isoprenaline. They also compare their findings to previously published structures of the β₂AR complex bound to other ligands (e.g., carazolol, salmeterol, BI167107) available in public databases like the Protein Data Bank (PDB).

Key Insights and Ideas

  • Agonist Efficacy Dictates Subtle but Crucial Structural Changes: Even though both salbutamol and isoprenaline activate the β₂AR, they induce measurably different conformational states in the receptor-G protein complex. This highlights that "activation" isn't a single state but a spectrum.
  • Orthosteric Binding Pocket Differences: The way salbutamol interacts within the receptor's primary binding site is weaker. This involves fewer and less stable hydrogen bonds and attenuated hydrophobic interactions compared to isoprenaline. This directly explains salbutamol's lower binding affinity and efficacy.
  • The "Rotamer Toggle Switch" is Key for Full Agonists: A critical finding is that isoprenaline (the full agonist) effectively triggers a conformational change known as the "rotamer toggle switch" in transmembrane helix 6 (TM6). Salbutamol, however, does not. This switch is crucial for achieving the fully active state and high efficacy.
  • Ionic Lock Disruption: While both agonists disrupt the "ionic lock" (another key activation mechanism), the full agonist isoprenaline also engages the rotamer toggle switch, leading to a larger TM6 movement and thus a more potent signaling response.
  • Intracellular Loop Interactions Matter for Desensitization: The study reveals that the intracellular loops (ICLs) of β₂AR interact differently with the Gs protein depending on the agonist. Salbutamol appears to induce stronger interactions between ICL2/ICL3 and the Gs protein. This might hinder receptor phosphorylation, a key step in desensitization, thereby explaining why partial agonists like salbutamol cause less desensitization.

Key Results

  • Structural Resolution: The study successfully determined the cryo-EM structures of the β₂AR-Gs complex bound to salbutamol at 3.26 Å and isoprenaline at 3.80 Å.
  • Active State Confirmation: Both structures represent active states of the receptor, indicated by the outward movement of TM6 compared to the inactive state.
  • Differential Binding Interactions:
    • Salbutamol exhibits weakened hydrogen bonding (e.g., involving S204 and N293) and hydrophobic interactions in the orthosteric pocket compared to isoprenaline.
  • Isoprenaline forms stronger hydrophobic interactions with residues in TM3, ECL2, and TM6.
  • TM6 Movement: Isoprenaline binding leads to a larger displacement of TM6 (14.6 Å) compared to salbutamol (14.1 Å), correlating with higher efficacy.
  • Functional Correlation: Mutating residue F290 (part of the rotamer toggle switch) significantly reduced isoprenaline-activated signaling but had little effect on salbutamol signaling, supporting the structural findings.
  • Enhanced Intracellular Interactions with Partial Agonists: Stronger interactions were observed between β₂AR's ICL2/ICL3 and the Gs protein when bound to salbutamol compared to isoprenaline.

Limitations and Future Work

  • C-terminal Truncation: The β₂AR construct used was truncated at residue K348, meaning the C-terminal tail, which is known to be involved in desensitization (e.g., phosphorylation by GRKs), could not be fully visualized. This limits direct structural insights into GRK-mediated desensitization.
  • Arrestin Interaction: The study focuses on the GPCR-Gs complex. While it speculates on how stronger intracellular interactions might affect phosphorylation and thus β-arrestin binding, direct structural evidence of β-arrestin binding in these specific complexes is not presented.
  • Future Directions: The authors suggest that further structural and functional studies are needed to fully elucidate the mechanisms of arrestin-mediated desensitization upon partial or full agonist binding. Understanding the detailed interplay between G protein and β-arrestin binding sites and how agonists differentially influence this competition remains an important area. Additionally, exploring the role of the C-terminal tail in these processes would be valuable.

Summary updated

Abstract

G protein-coupled receptors (GPCRs) are responsible for most cytoplasmic signaling in response to extracellular ligands with different efficacy profiles. Various spectroscopic techniques have identified that agonists exhibiting varying efficacies can selectively stabilize a specific conformation of the receptor. However, the structural basis for activation of the GPCR-G protein complex by ligands with different efficacies is incompletely understood. To better understand the structural basis underlying the mechanisms by which ligands with varying efficacies differentially regulate the conformations of receptors and G proteins, we determined the structures of β<sub>2</sub>AR-Gα<sub>s</sub>[Formula: see text]γ bound with partial agonist salbutamol or bound with full agonist isoprenaline using single-particle cryo-electron microscopy at resolutions of 3.26 Å and 3.80 Å, respectively. Structural comparisons between the β<sub>2</sub>AR-Gs-salbutamol and β<sub>2</sub>AR-Gs-isoprenaline complexes demonstrated that the decreased binding affinity and efficacy of salbutamol compared with those of isoprenaline might be attributed to weakened hydrogen bonding interactions, attenuated hydrophobic interactions in the orthosteric binding pocket and different conformational changes in the rotamer toggle switch in TM6. Moreover, the observed stronger interactions between the intracellular loop 2 or 3 (ICL2 or ICL3) of β<sub>2</sub>AR and Gα<sub>s</sub> with binding of salbutamol versus isoprenaline might decrease phosphorylation in the salbutamol-activated β<sub>2</sub>AR-Gs complex. From the observed structural differences between these complexes of β<sub>2</sub>AR, a mechanism of β<sub>2</sub>AR activation by partial and full agonists is proposed to provide structural insights into β<sub>2</sub>AR desensitization.
BibTeX
@inproceedings{yang2020different,
  author = {Fan Yang and Shenglong Ling and Yingxin Zhou and Yanan Zhang and Pei Lv and Sanling Liu and Wei Fang and Wenjing Sun and Liaoyuan A. Hu and Longhua Zhang and Pan Shi and Changlin Tian},
  title = {{Different conformational responses of the β2-adrenergic receptor-Gs complex upon binding of the partial agonist salbutamol or the full agonist isoprenaline}},
  booktitle = {National},
  year = {2020},
  doi = {10.1093/nsr/nwaa284},
}
Figure